Physician profile
Walter Gessler
NPI 1265424766
$1,353.30
in general payments reported to CMS, 2019-2025
24 companies · $270 in 2025
The $270 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $114 · 2022: $14.12 · 2023: $111 · 2024: $328 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $215.90 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $199.03 | 2019-2025 | Doc Band |
| Tris Pharma INC | $112.23 | 2019-2024 | Dyanavel Xr |
| Corium, LLC | $105.54 | 2024-2025 | Azstarys |
| Pfizer INC. | $101.18 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $84.08 | 2019-2024 | Vaxelis, M-M-R II, Gardasil 9 |
| Glaxosmithkline, LLC. | $83.06 | 2019-2025 | Bexsero, Pediarix |
| Genentech USA, INC. | $63.92 | 2019 | |
| Supernus Pharmaceuticals, INC. | $62.65 | 2025 | Qelbree |
| Seqirus USA INC | $38.94 | 2024-2025 | Flucelvax |
| Sanofi Pasteur INC. | $31.21 | 2025 | |
| Aquestive Therapeutics, INC. | $29.53 | 2024 | |
| Mylan Pharmaceuticals INC. | $28.74 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $23.68 | 2025 | Neffy |
| Neos Therapeutics, LP | $22.70 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $19.33 | 2019 | |
| Fortovia Therapeutics, INC. | $19.24 | 2020 | |
| Collegium Pharmaceutical, INC. | $18.88 | 2025 | Jornay Pm |
| Novartis Pharmaceuticals Corporation | $18.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.15 | 2024 | Flumist Quadrivalent |
| Avion Pharmaceuticals | $16.89 | 2023 | Methylphenidate Hydrochloride |
| Phadia US INC. | $13.75 | 2025 | Immunocap |
| Kaleo, INC. | $13.37 | 2019 | |
| Shire North American Group INC | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Gessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.